ReviewCell regeneration (London, England)2026
Signaling pathways regulating cardiac regeneration.
Review in Cell regeneration (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cardiac regeneration represents a pivotal frontier in addressing cardiovascular diseases, the leading global cause of mortality. This review integrates current advancements in understanding the molecular mechanisms driving cardiomyocyte proliferation and myocardial repair. Key signaling pathways-including Hippo/YAP, Wnt/β-catenin, NRG1-ErbB, MAPK, and Notch-orchestrate cardiomyocyte dedifferentiation, cell cycle re-entry, and tissue remodeling. Hippo inhibition promotes cardiomyocyte proliferation and cytoskeletal reorganization, while Wnt/β-catenin exhibits dual roles depending on developmental context and injury phase. NRG1-ErbB and MAPK/ERK pathways integrate metabolic reprogramming and paracrine signaling to enhance regeneration. Transcriptional regulators such as Meis1, GATA4, and Tbx20 modulate cell cycle dynamics, while extracellular matrix components (e.g., Agrin, FSTL1, POSTN) and growth factors (PDGF, FGF, VEGF, Ang-1) reshape the regenerative microenvironment. Despite progress, challenges persist in spatiotemporal control of proliferation, interspecies pathophysiological disparities, and therapeutic delivery precision. Emerging technologies-engineered myocardial grafts, transient modified mRNA systems (e.g., SMRTs), and hypoxia-mediated metabolic switching-highlight translational potential. Future strategies demand integration of multi-omics, biomaterials, and combinatorial interventions to bridge mechanistic insights with clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.